Genmab’s strategy for going commercial
As Genmab moves toward commercialization, it plans to innovate the process
As Genmab moves toward commercialization for the first time, it plans to innovate the process.
Genmab is preparing to join the expanding ranks of biotechs taking on commercialization, and CEO Jan van de Winkel is approaching commercial strategy with the same innovative eye he’s applied to development.
The company and partner Seagen Inc. (NASDAQ:SGEN) are planning to submit a BLA this quarter for first-in-class antibody-drug conjugate tisotumab vedotin, positioning the therapy for a 2021 decision.
An approval would be Genmab’s first for a product it will commercialize itself. The biotech has focused on antibody discovery and development for the past 22 years. It started planning a commercial move about three years ago, shifting its partnering strategy to retain more commercial rights.
“We have three products on the market with partners and are now sustainably profitable. We can afford to hold on to ownership of products and in the coming years, could potentially have two product launches where we own at least 50%,” van de Winkel told BioCentury.
The former three products — Darzalex daratumumab, which